Cancer Immunotherapy

WHAT WE DO

In recent years, immunotherapy, cell therapy, and gene therapy have taken center stage as new approaches for eliminating malignant tumors

TSA, also called neoantigens, are somatic mutations present in individual cancers, and are truly foreign proteins expressed only on cancer cells (TSAs are not found on normal healthy tissues). Emerging evidence suggests ideal and successful cancer immunotherapies which target neoantigens, combined with immune checkpoint inhibition therapy, achieve greater therapeutic effects.
One of the major challenges with personalized neoantigen therapeutic vaccines, however, has been that the current neoantigen prediction algorithms require further optimization, as current neoepitope prediction methods result in low rates of validation. In fact, studies show less than 3% accuracy rate (~2%) of neopeptide CD8+ T cell stimulation.
CANCER IMMUNOTHERAPY

A technology that overcomes this lack of accuracy is our proprietary nanoshell delivery mechanism

ABC’s neoantigen cancer vaccine achieves much higher accuracy with its novel design considerations and proprietary nanoshell delivery mechanism.  ABC’s neoantigen cancer vaccine reduces reactogenic adverse effects and triggers precise multivalent immune potentiation, resulting in a yield of nearly 60% accuracy rate (>58%) in CD8+ T cell stimulation when targeting pMMR Colorectal Cancers. ABC hopes that the high potency and safety profile of our vaccine renders it capable of minimizing future vaccination regimen and duration in treatment protocol while achieving strong results for the patients.
The first neoantigen cancer vaccines to be produced for patients in our Phase 1 Clinical Trial will target pMMR CRC, HPV-related Cancers (head & neck and cervical) and Prostate Cancer. ABC believes that a personalized cancer vaccine will be available for patients in the future of oncology medicine.
OUR TECH

Cancer
Immunotherapy

Herpes Virus
Immunotherapy

Partnership

Explore a potentional partnership